ViCentra Secures $85M Series D to Scale Kaleido Insulin Patch Pump Manufacturing and US Market Entry
核心洞察
ViCentra (搜索) raised $85 million in Series D funding led by Innovation Industries (搜索) to accelerate manufacturing scale-up and launch of the next-generation Kaleido 2 insulin patch pump in Europe.
The Kaleido system is positioned as the smallest, lightest, and most precise insulin patch pump in its class, designed as a lifestyle product with customizable aluminum shells in ten color options.
Strong commercial uptake in Germany, France, and the Netherlands has driven demand beyond initial expectations, with the company now preparing for U.S. market entry.
ViCentra (搜索), a European medical device company focused on insulin delivery innovation, has successfully closed an upsized $85 million Series D financing round to accelerate manufacturing scale-up and market expansion of its Kaleido insulin patch pump system. The funding was led by new investor Innovation Industries (搜索), with matching participation from existing investors Partners in Equity (搜索) and Invest-NL (搜索), alongside continued support from EQT Life Sciences (搜索) and Health Innovations (搜索).
The fresh capital will enable ViCentra (搜索) to scale manufacturing operations, launch the next-generation Kaleido 2 patch pump across Europe, and prepare for entry into the U.S. market. The company reports that strong initial commercial uptake in Germany, France, and the Netherlands has driven demand beyond initial expectations.
Revolutionary Design Approach
Kaleido distinguishes itself as the smallest, lightest, and most precise insulin patch pump in its class, uniquely positioned as a lifestyle product rather than a traditional medical device. The system features premium materials and offers users the ability to select from ten preset aluminum shell color options, enabling personalization and self-expression alongside glycemic control.
"Kaleido is a true disruptor — small, discreet, featherlight, and beautifully designed. It empowers people with diabetes by offering a more personal and distinctive choice in both function and style," said Tom Arnold, Chief Executive Officer at ViCentra (搜索). "Built with empathy and precision, it honors those who live with diabetes every day."
The device integrates with Diabeloop's self-learning automated insulin delivery algorithm and maintains compatibility with the Dexcom (搜索) CGM sensor, positioning ViCentra (搜索) at the forefront of next-generation diabetes care technology.
Market Dynamics and Growth Potential
The global insulin delivery market represents one of the largest and fastest-growing medical device segments, driven by rising diabetes prevalence and increasing demand for solutions that combine clinical effectiveness with everyday usability. According to ViCentra (搜索), the insulin pump market alone is projected to reach over $14 billion by 2034.
Patch pumps represent the fastest-growing segment within the insulin delivery market, signaling a broader industry shift toward compact, wearable, and patient-centric solutions. This trend reflects the growing demand for diabetes management tools that seamlessly integrate into patients' daily lives.
Strategic Investment and Future Plans
"ViCentra (搜索) is redefining insulin pump therapy with a platform that truly centers the user experience – combining clinical performance with design simplicity and wearability," commented Caaj Greebe, Partner at Innovation Industries (搜索). "At Innovation Industries, we invest in pioneering companies that blend world-class technology with clear commercial potential. ViCentra exemplifies this by delivering a next-generation system addressing the urgent need for better treatment options in diabetes care."
The funding round demonstrates strong investor confidence in ViCentra (搜索)'s technology platform and commercial strategy. With this financing, the company aims to meet surging European demand while fast-tracking its entry into the U.S. market, representing what Arnold describes as "a pivotal moment — for ViCentra, and for the community we serve."
ViCentra (搜索) will showcase its technology at the 61st Annual Meeting of the European Association for the Study of Diabetes (EASD), taking place September 15-19, 2025, in Vienna, Austria, where the company plans to engage with key clinicians, investors, and strategic partners to explore advancement opportunities in insulin delivery.